WuXi Biologics (Cayman) Inc (WXXWY)
3.603
-0.12
(-3.15%)
USD |
OTCM |
May 07, 11:19
WuXi Biologics Cash from Operations (TTM): 658.80M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 658.80M |
June 30, 2023 | 966.46M |
December 31, 2022 | 794.62M |
June 30, 2022 | 632.02M |
December 31, 2021 | 534.98M |
June 30, 2021 | 342.30M |
December 31, 2020 | 279.51M |
June 30, 2020 | 200.73M |
Date | Value |
---|---|
December 31, 2019 | 172.53M |
June 30, 2019 | 124.99M |
December 31, 2018 | 111.65M |
June 30, 2018 | 39.28M |
December 31, 2017 | 53.24M |
June 30, 2017 | 53.73M |
December 31, 2016 | 11.40M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
124.99M
Minimum
Jun 2019
966.46M
Maximum
Jun 2023
470.69M
Average
438.64M
Median
Cash from Operations (TTM) Benchmarks
Wuxi AppTec Co Ltd | -- |
Zai Lab Ltd | -198.18M |
I-MAB | -- |
Gracell Biotechnologies Inc (DELISTED) | -- |
Sinovac Biotech Ltd | -- |